Oncternal, FDA In Pact For Pivotal Study Design For Zilovertam In Mantle Cell Lymphoma

The FDA and Oncternal Therapeutics Inc ONCT have agreed on key elements of the Company's Phase 3 trial of zilovertamab for relapsed or refractory mantle cell lymphoma (MCL).

  • The FDA has also reviewed and agreed upon the key design features and operational details of Oncternal's Phase 3 trial protocol and Statistical Analysis Plan, which is being finalized based on the FDA's input.
  • The study will randomize patients with relapsed or refractory MCL who have experienced stable disease or partial response after receiving four months of oral ibrutinib therapy.
  • All patients will continue receiving oral ibrutinib. 
  • The primary endpoint will be progression-free survival (PFS). 
  • Study ZILO-301, expected to initiate in Q2 of 2022, will be conducted internationally in at least 50 centers.
  • The Company is also planning to conduct Study ZILO-302, an open-label companion study of zilovertamab plus ibrutinib for patients with progressive disease during the initial four months of ibrutinib monotherapy from Study ZILO-301.
  • The Company shared updated data for zilovertamab in combination with Ibrutinib at ASH 2021.
  • The data showed an objective response rate of 81% and a complete response rate of 35% for the combination therapy.
  • Price Action: ONCT shares are up 8.12% at $2.53 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefsPhase 3 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!